Skip to main content
    B

    BioRestorative Therapies Inc (BRTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.42
    -0.07 (-4.70%)

    Market Cap: $2.06M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    BioRestorative Therapies Inc (BRTX) Financials: Revenue, Profit and Cash Flow

    Updated May 14, 2026. Financial statements from company filings, amounts in US dollars.

    BioRestorative Therapies reported revenue of $359.70K for the fiscal year ended Dec 31, 2025, down 10.3% from the year before. That year, net income was -$14.24M with a net margin of -3959.4%, operating cash flow was -$10.79M and free cash flow was -$10.91M. The quarter ended Mar 31, 2026 had revenue of $23.17K and net income of -$2.15M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $36.35K, a compound annual rate of 29.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$359.70K-10.3%93.4%-4350.1%-3959.4%
    Dec 2024$401.00K+175.0%93.0%-2881.6%-2239.2%
    Dec 2023$145.80K+21.7%100.0%-10439.5%-7145.2%
    Dec 2022$119.80K+160.4%100.0%-15838.1%-11037.0%
    Dec 2021$46.00K-40.3%100.0%-57191.0%-96311.5%
    Dec 2020$77.00K-40.8%100.0%-3574.1%-14639.9%
    Dec 2019$130.00K+17.1%100.0%-6486.2%-11267.6%
    Dec 2018$111.00K+37.0%100.0%-6889.8%-11277.3%
    Dec 2017$81.00K+122.8%-220.1%-10338.6%-11660.1%
    Dec 2016$36.35KN/A99.7%-21447.6%-23755.4%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Mar 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$359.70K$401.00K$145.80K$119.80K$46.00K$77.00K$130.00K$111.00K$81.00K$36.35K
    Cost of revenue$23.84K$28.07K$0$0$0$0$0$0$259.26K$102
    Gross profit$335.86K$372.93K$145.80K$119.80K$46.00K$77.00K$130.00K$111.00K-$178.26K$36.25K
    Research and development$10.09M$6.71M$4.03M$3.51M$729.06K$876.83K$1.72M$1.51M$0$0
    Operating income-$15.65M-$11.56M-$15.22M-$18.97M-$26.31M-$2.75M-$8.43M-$7.65M-$8.37M-$7.80M
    Net income-$14.24M-$8.98M-$10.42M-$13.22M-$44.30M-$11.27M-$14.65M-$12.52M-$9.44M-$8.64M
    EBITDA-$14.30M-$9.41M-$10.80M-$13.11M-$25.09MN/A-$3.73M-$5.35M$0$0
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Revenue$23.17K$19.60K$11.80K$303.30K$25.00K$43.30K$233.60K$89.10K$35.00K$19.30K$30.70K$64.50K
    Gross profit$15.79K$17.96K$1.23K$294.57K$22.09K$39.96K$215.36K$82.61K$35.00K$19.30K$30.70K$64.50K
    Operating income-$3.39M-$3.83M-$3.71M-$3.31M-$4.81M-$2.69M-$2.29M-$2.47M-$4.11M-$3.22M-$3.10M-$3.12M
    Net income-$2.15M-$3.21M-$3.04M-$2.66M-$5.34M-$1.64M-$1.09M-$4.03M-$2.22M-$2.30M$4.77M-$5.71M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $1.51M were 37.0% of total assets of $4.08M, against total liabilities of $3.72M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$4.08M$12.28M$12.61M$16.43M$22.45M$4.35M$1.47M$1.19M$1.76M$1.58M
    Current assets$3.14M$11.14M$11.39M$15.13M$21.47M$3.19M$68.86K$180.99K$519.71K$61.68K
    Cash and equivalents$1.51M$547.89K$884.38K$1.71M$21.03M$3.06M$1.66K$117.52K$451.68K$31.82K
    Total liabilities$3.72M$3.75M$2.61M$6.14M$856.50K$5.68M$14.24M$9.83M$8.60M$6.58M
    Short-term debtN/A$324.63K$162.32K$139.33K$58.97K$0$7.15M$3.63M$3.47M$1.86M
    Long-term debtN/AN/AN/AN/A$191.03K$4.27M$0$523.89K$194.28K$297.76K
    Shareholder equity$356.74K$8.53M$10.00M$10.29M$21.60M-$1.33M-$12.78M-$8.64M-$6.84M-$5.00M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets$4.64M$4.08M$5.64M$8.52M$10.33M$12.28M$14.57M$16.12M$17.95M$12.61M$13.80M$13.30M
    Total liabilities$1.61M$3.72M$3.44M$3.67M$4.18M$3.75M$4.58M$5.32M$3.45M$2.61M$975.03K$896.43K
    Cash and equivalents$3.11M$1.51M$602.44K$1.56M$1.23M$547.89K$1.49M$2.25M$1.16M$884.38K$2.44M$1.78M
    Shareholder equity$3.03M$356.74K$2.21M$4.85M$6.14M$8.53M$9.99M$10.80M$14.50M$10.00M$12.83M$12.40M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$10.79M-$8.23M-$6.43M-$5.91M-$3.33M-$1.96M-$6.92M-$5.10M-$3.85M-$5.00M
    Capital expenditures$116.07K$106.19K$171.04K$265.22K$30.66K$0$35.63K$12.87K$3.62K$188.76K
    Free cash flow-$10.91M-$8.34M-$6.60M-$6.18M-$3.36M-$1.96M-$6.95M-$5.12M-$3.86M-$5.19M
    Dividends paid$270.57K$623.80K$569.07KN/AN/AN/AN/AN/AN/AN/A
    Share repurchases$177.95K$0N/AN/AN/AN/AN/AN/AN/AN/A
    Investing cash flow$8.90M$514.53K$3.25M-$13.40M-$30.66K$0-$35.63K-$12.87K-$3.62K-$188.76K
    Financing cash flow$2.85M$7.38M$2.35M$0$21.32M$5.03M$6.84M$4.78M$4.28M$5.06M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow-$3.81M-$2.42M-$2.90M-$2.69M-$2.78M-$2.35M-$1.70M-$1.87M-$2.32M-$1.59M-$1.18M-$1.28M
    Capital expenditures$0$79.67K$3$3$36.40K$12.43K$58.46K$35.30K$0$70.02K$11.95K$29.05K
    Free cash flow-$3.81M-$2.49M-$2.90M-$2.69M-$2.82M-$2.36M-$1.76M-$1.90M-$2.32M-$1.66M-$1.19M-$1.31M
    Last 12 quarters

    Frequently Asked Questions About BRTX

    What is BioRestorative Therapies' annual revenue?

    BioRestorative Therapies reported revenue of $359.70K for the fiscal year ended Dec 31, 2025.

    How fast is BioRestorative Therapies' revenue growing?

    Revenue was down 10.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 44.3%.

    Is BioRestorative Therapies profitable?

    No. BioRestorative Therapies reported net income of -$14.24M for the fiscal year ended Dec 31, 2025, with a net margin of -3959.4%.

    How much free cash flow does BRTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$10.79M minus capital expenditures of $116.07K produced free cash flow of -$10.91M.

    How much debt does BioRestorative Therapies have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $1.51M.